Plasma atrial natriuretic peptide concentrations in horses with heart disease: a pilot study.

This study explores the potential use of atrial natriuretic peptide (ANP), a cardiovascular biomarker, in measuring the severity of heart disease in horses. It shows that horses with heart disease associated with an enlarged left atrium have significantly higher concentrations of ANP than others. These findings suggest the peptide could be key in identifying this specific heart abnormality in horses.

About the Study

• In this pilot study, the researchers explored the possible role of Atrial Natriuretic Peptide (ANP) as a biomarker in gauging the severity of heart disease in horses. ANP is a hormone that can help regulate blood pressure and body fluid volume.
• They formed three groups of horses: Group A (6 horses) had heart disease, but no abnormal heart chamber size and function; Group B (5 horses) had heart disease and displayed abnormalities such as left atrial enlargement, dysfunction, and/or left ventricular enlargement; Group C (13 horses) had no discernible heart disease.
• Plasma ANP concentrations (Cp(ANP)) were compared across all three groups.

Key Findings

• The median ANP concentration was significantly higher in Group B than in Group A and Group C. This indicates that the level of this peptide was much higher in horses whose heart disease was associated with enlargement of the left atrium.
• Through a backwards stepwise multiple linear regression analysis, it was found that in horses with heart disease, Cp(ANP) was associated with the dimensions of the left atrium, but there was no correlation with left ventricular size or function of either the left atrium or left ventricle.

Implications and Future Research

• The findings from this pilot study suggest that Cp(ANP) could potentially be used as a biomarker to detect enlargement of the left atrium in horses. This can greatly enhance the diagnostic process in equine veterinary cardiology.
• The correlation between Cp(ANP) and the severity of heart disease suggests that this biomarker could be instrumental in creating treatment plans and managing horse heart disease more effectively.
• However, due to the small sample size, the researchers recommend larger prospective studies to validate these early findings.